the efficacy and safety of mirtazapin monotherapy on major deppressive disorder

the efficacy and safety of mirtazapin monotherapy on major deppressive disorder - the efficacy and safety of mirtazapin monotherapy on major deppressive disorder

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024287

Enrollment

200

Registered

2016-10-04

Start date

2016-10-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

major depressive disorder

Interventions

using mirtazapine 15 to 45mg for 6week

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: major depressive disorder (DSM-5)

Exclusion criteria

Exclusion criteria: attempt to suicide

Design outcomes

Primary

Measure	Time frame
Quick Inventory of Depressive Symptomatology	—

Countries

Japan

Contacts

Public ContactTsutsumi Takahiro

Tokyo Women's medical university Department of Psychiatry

tsutsumi.takahiro@twmu.ac.jp0333538111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026